Barton Shane
Barton Shane's purchase track record
Barton Shane has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/27/2024 | BIOA | $47K | -73.8% | -81.8% | -2.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Precision BioSciences to Present HBV Data at AASLD 2026. Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.
Transaction History
| BIOA | ▲ Buy | Option Exercise | 7,861 | $34K | 6/30/2026 | View on chart |
| BIOA | ▲ Buy | Option Exercise | 4,290 | $47K | 6/30/2026 | View on chart |
| BIOA | ▲ Buy | Option Exercise | 4,000 | $34K | 6/30/2026 | View on chart |
| BIOA | ▲ Buy | Option Exercise | 4,065 | $17K | 6/30/2026 | View on chart |
| BIOA | ▼ Sell | Open Market | 20,216 | $509K | 6/30/2026 | View on chart |
| BIOA | ▲ Buy | Option Exercise | 8,958 | $39K | 6/29/2026 | View on chart |
| BIOA | ▲ Buy | Option Exercise | 9,301 | $101K | 6/29/2026 | View on chart |
| BIOA | ▲ Buy | Option Exercise | 7,261 | $61K | 6/29/2026 | View on chart |
| BIOA | ▲ Buy | Option Exercise | 14,198 | $62K | 6/29/2026 | View on chart |
| BIOA | ▼ Sell | Open Market | 42,350 | $1.1M | 6/29/2026 | View on chart |
| BIOA | ▲ Buy | Open Market | 2,632 | $47K | 9/27/2024 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 6,060 | — | 6/7/2023 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 12,722 | — | 3/3/2023 | View on chart |
| DTIL | ▲ Buy | Option Exercise | 6,061 | — | 6/7/2022 | View on chart |
| DTIL | ▲ Buy | Grant | 761 | $3K | 2/28/2022 | View on chart |
| DTIL | ▲ Buy | Grant | 604 | $6K | 8/31/2021 | View on chart |
| DTIL | ▲ Buy | Grant | 1,294 | $6K | 2/26/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
BioAge Labs to Present at Investor Conferences
BioAge Labs announced it will present at upcoming investor conferences, providing a platform to share company updates with the market. The stock is currently trading near its 52-week low, which may increase attention from investors seeking value. This corporate activity adds context to the recent whale alerts noted in healthcare stocks.
BioAge Labs to Present at Investor Conferences. BioAge Labs announced it will present at upcoming investor conferences, providing a platform to share company updates with the market. The stock is currently trading near its 52-week low, which may increase attention from investors seeking value. This corporate activity adds context to the recent whale alerts noted in healthcare stocks.